Nabriva, along with its collaborators, will exhibit a poster presentation on the in vitro activity of lefamulin against Staphylococcus aureus isolated from the lower respiratory tract of children with cystic fibrosis. XENLETA® (lefamulin) is a first-in-class pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia (CABP).
Session Title: Respiratory Infections – Bacterial
Poster Title: “In Vitro Activity of Lefamulin against Staphylococcus aureus isolated from the Lower Respiratory Tract of Children with Cystic Fibrosis”
Session ID: 1058520
Presenting Author: Dr.
About Nabriva Therapeutics plc
Any statements in this press release about future expectations, plans and prospects for
Source: Nabriva Therapeutics US, Inc